Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Therapeutic Potential of Bone Marrow- and Ovarian/Endometrium-Derived Mesenchymal Stem Cells in Regulating Ovarian Function in a Streptozotocin-Induced Diabetes Mellitus Rat Model

Tunç E., Dizeci N., Pınarlı FA., Yıldırım Ö.

Animal Study on Hair & Scalp, Systemic / IV, published in Reprod Sci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Reprod Sci (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41787057
PMCID
PMC13179166
DOI
10.1007/s43032-026-02063-1

Abstract (original English)

Streptozotocin (STZ)-induced pancreatic damage leads to β-cell injury and hyperglycemia, providing a controlled model to study ovarian dysfunction. This study aimed to investigate the potential of mesenchymal stem cells (MSCs) derived from ovary, endometrium, and bone marrow to restore ovarian function in rats with STZ-induced diabetes mellitus, due to their ease of isolation and capacity for differentiation. Fifty female Sprague-Dawley rats were divided into five groups: control, STZ-induced pancreatic damage, and STZ-induced rats treated with ovarian, endometrium, or bone marrow-derived MSCs. Pancreatic damage was induced via intraperitoneal injection of 45 mg/kg STZ in 32 rats. Rats with blood glucose ≥ 200 mg/dL were considered hyperglycemic and monitored for six weeks. MSCs were isolated from healthy donors, cultured, characterized by flow cytometry, and labeled with BrdU. At the third week, 2 × 10⁶ cells in PBS were injected into the ovaries via the endometrial canal. At the sixth week, rats were sacrificed, and ovarian tissues were analyzed histopathologically and immunohistochemically. The results showed that streptozotocin-induced diabetes mellitus led to structural alterations in ovarian follicles. Notably, bone marrow- and ovary-derived MSCs were effective in ameliorating these changes, while endometrium-derived MSCs showed moderate effects. These findings suggest th

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
OvaryEndometriumBone Marrow CellsCells, CulturedMesenchymal Stem CellsAnimalsRatsRats, Sprague-DawleyDiabetes Mellitus, ExperimentalBlood Glucose

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research